Pancreatic Cancer Daraxonrasib skin rash: What actually helps?

@casey1959
My understanding is The FDA approval is for Adults with metastatic pancreatic adenocarcinoma who
(1) have received at least one prior systemic therapy, or
(2) are not candidates for multi-agent systemic therapy.

Details:
* Cancer type: pancreatic adenocarcinoma (PDAC) — the usual ductal pancreatic cancer, not pancreatic neuroendocrine cancer or other pancreatic tumors.
* Stage: it must be metastatic, meaning the cancer has spread to distant sites.
* Prior treatment: at least one systemic treatment is required, unless the patient isn’t a candidate for multi-agent therapy.
* RAS mutation is not required by the FDA label. The approval covers metastatic PDAC with or without an identified RAS mutation; no companion diagnostic is required.
* It is a once-daily oral targeted therapy, not conventional chemotherapy.

Whether or not a Whipple procedure was done earlier isn't a criteria.

A doctor can prescribe RASONQUE outside the exact FDA-approved indication. That is called off-label prescribing. The FDA specifically says that once a drug is approved, healthcare providers generally may prescribe it for an unapproved use when they judge it medically appropriate for an individual patient.

@nbcesq Ty and I hope things go well with you too.